undamentalytics Newsletter
Sign in

Assembly Biosciences, Inc. balance sheet

At the end of fiscal 2025, Assembly Biosciences, Inc. had total assets of $258m, total liabilities of $50.8m and shareholders' equity of $207m. It held $58.5m in cash against $0 of debt: net cash of $58.5m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents2982414759465220385832
Receivables02231010011
Total current assets5412322328322415497134116255328
Goodwill1313131313——————
Total assets98169268340283191102137119258331
Accounts payable——425320111
Deferred revenue (current)04656———31383716
Total current liabilities713182424161639484923
Total debt00000000000
Total liabilities1856576743221996865125
Shareholders' equity80113211273241169834133207306
Net debt (negative = net cash)−29−82−41−47−59−46−52−20−38−58−32
Shares outstanding——————4m5m7m—20m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ASMB vs CGENASMB vs VRDNASMB vs WVE

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Assembly Biosciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Assembly Biosciences, Inc.